{"transactions":[{"id":689439,"issuer":{"id":6741,"kind":"organization","name":"Amanat Acquisition Corp."},"owners":[{"id":24198,"kind":"person","name":"Kulkarni Sandeep Chidambar","position":1,"cik":"0001945691","reported_name":"Kulkarni Sandeep Chidambar","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Director and Chairman"}}],"security":"Class B Ordinary Shares","published_at":"2026-08-12T11:45:37.000Z","date":"2026-07-02","kind":"other","planned":false,"acquired":false,"shares":281250,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Amanat Sponsor Holdings LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Class B ordinary shares will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of the Issuer's initial business combination or earlier at the option of the holder on a one-for-one basis, subject to adjustment for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights as described under the heading \"Description of Securities--Founder Shares and Private Placement Shares\" in the Issuer's registration statement on Form S-1 (File No. 333-295170) (\"Registration Statement\") and have no expiration date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"281,250 Class B Ordinary Shares were forfeited to the Issuer by Amanat Sponsor Holdings LLC (the \"Sponsor\") at no cost, in connection with the expiration of the underwriters' over-allotment option as described in the Registration Statement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Class B ordinary shares will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of the Issuer's initial business combination or earlier at the option of the holder on a one-for-one basis, subject to adjustment for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights as described under the heading \"Description of Securities--Founder Shares and Private Placement Shares\" in the Issuer's registration statement on Form S-1 (File No. 333-295170) (\"Registration Statement\") and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Class B ordinary shares will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of the Issuer's initial business combination or earlier at the option of the holder on a one-for-one basis, subject to adjustment for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights as described under the heading \"Description of Securities--Founder Shares and Private Placement Shares\" in the Issuer's registration statement on Form S-1 (File No. 333-295170) (\"Registration Statement\") and have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Sponsor is the record holder of the securities reported herein. The Reporting Person is the sole managing member of the Sponsor and has voting and investment discretion with respect to the shares held by the Sponsor. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":1875000,"derivative":{"underlying":"Class A Ordinary Shares","underlying_shares":281250},"source":{"system":"sec-edgar","filing":"0001945691-26-000008","document":"form4-08122026_110833.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1945691/000194569126000008/form4-08122026_110833.xml","form_type":"4"}},{"id":766263,"issuer":{"id":6741,"kind":"organization","name":"Amanat Acquisition Corp."},"owners":[{"id":24198,"kind":"person","name":"Kulkarni Sandeep Chidambar","position":1,"cik":"0001945691","reported_name":"Kulkarni Sandeep Chidambar","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Director and Chairman"}}],"security":"Class A Ordinary Shares","published_at":"2026-05-22T23:16:11.000Z","date":"2026-05-20","kind":"purchase","planned":false,"acquired":true,"shares":300000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the 300,000 private placement shares purchased by Amanat Sponsor Holdings LLC, the Issuer's sponsor, pursuant to the Private Placement Shares Purchase Agreement dated May 20, 2026 entered into with the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the 300,000 private placement shares purchased by Amanat Sponsor Holdings LLC, the Issuer's sponsor, pursuant to the Private Placement Shares Purchase Agreement dated May 20, 2026 entered into with the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amanat Sponsor Holdings LLC is the record holder of the securities reported herein. Dr. Sandeep Kulkarni is the sole managing member of our sponsor and has voting and investment discretion with respect to the ordinary shares held of record by Amanat Sponsor Holdings LLC. Dr. Sandeep Kulkarni disclaims any beneficial ownership of the securities held by Amanat Sponsor Holdings LLC other than to the extent of any pecuniary interest he may have therein, directly or indirectly."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Amanat Sponsor Holdings LLC is the record holder of the securities reported herein. Dr. Sandeep Kulkarni is the sole managing member of our sponsor and has voting and investment discretion with respect to the ordinary shares held of record by Amanat Sponsor Holdings LLC. Dr. Sandeep Kulkarni disclaims any beneficial ownership of the securities held by Amanat Sponsor Holdings LLC other than to the extent of any pecuniary interest he may have therein, directly or indirectly."}],"balance_after":300000,"source":{"system":"sec-edgar","filing":"0001213900-26-060703","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1945691/000121390026060703/ownership.xml","form_type":"4"}},{"id":820094,"issuer":{"id":5413,"kind":"organization","name":"Zura Bio Ltd"},"owners":[{"id":24198,"kind":"person","name":"Kulkarni Sandeep Chidambar","position":1,"cik":"0001945691","reported_name":"Kulkarni Sandeep Chidambar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Share Option (Right to Buy)","published_at":"2026-04-02T22:00:17.000Z","date":"2026-04-01","kind":"grant","planned":false,"acquired":true,"shares":894000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One fourth (1/4th) of the shares subject to the option award shall vest on April 1, 2027, and one twelfth (1/12th) of the remaining shares subject to the option award shall vest in equal quarterly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":894000,"derivative":{"exercise_price":6.03,"expiration_date":"2036-04-01","underlying":"Class A Ordinary Shares","underlying_shares":894000},"source":{"system":"sec-edgar","filing":"0001945691-26-000005","document":"form4-04022026_060413.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1945691/000194569126000005/form4-04022026_060413.xml","form_type":"4"}},{"id":932500,"issuer":{"id":5413,"kind":"organization","name":"Zura Bio Ltd"},"owners":[{"id":24198,"kind":"person","name":"Kulkarni Sandeep Chidambar","position":1,"cik":"0001945691","reported_name":"Kulkarni Sandeep Chidambar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Share Option (Right to Buy)","published_at":"2026-01-23T22:56:36.000Z","date":"2026-01-21","kind":"grant","planned":false,"acquired":true,"shares":2934107,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One fourth (1/4th) of the shares subject to the option award shall vest on January 21, 2027, and one twelfth (1/12th) of the remaining shares subject to the option award shall vest in equal quarterly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":2934107,"derivative":{"exercise_price":6.32,"expiration_date":"2036-01-21","underlying":"Class A Ordinary Shares","underlying_shares":2934107},"source":{"system":"sec-edgar","filing":"0001945691-26-000003","document":"form4-01232026_100132.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1945691/000194569126000003/form4-01232026_100132.xml","form_type":"4"}},{"id":1012663,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":24198,"kind":"person","name":"Kulkarni Sandeep Chidambar","position":1,"cik":"0001945691","reported_name":"Kulkarni Sandeep Chidambar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-10-28T22:30:05.000Z","date":"2025-10-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":226000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland (\"Parent\"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the \"Shares\"), issued and outstanding immediately prior to the effective time of the merger (the \"Effective Time\"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":15.54,"underlying":"Common Stock","underlying_shares":226000},"source":{"system":"sec-edgar","filing":"0001945691-25-000006","document":"form4-10282025_061001.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1945691/000194569125000006/form4-10282025_061001.xml","form_type":"4"}},{"id":1012662,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":24198,"kind":"person","name":"Kulkarni Sandeep Chidambar","position":1,"cik":"0001945691","reported_name":"Kulkarni Sandeep Chidambar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-10-28T22:30:05.000Z","date":"2025-10-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":254207,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland (\"Parent\"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the \"Shares\"), issued and outstanding immediately prior to the effective time of the merger (the \"Effective Time\"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":9.46,"underlying":"Common Stock","underlying_shares":254207},"source":{"system":"sec-edgar","filing":"0001945691-25-000006","document":"form4-10282025_061001.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1945691/000194569125000006/form4-10282025_061001.xml","form_type":"4"}},{"id":1012661,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":24198,"kind":"person","name":"Kulkarni Sandeep Chidambar","position":1,"cik":"0001945691","reported_name":"Kulkarni Sandeep Chidambar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-10-28T22:30:05.000Z","date":"2025-10-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":503478,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland (\"Parent\"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the \"Shares\"), issued and outstanding immediately prior to the effective time of the merger (the \"Effective Time\"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":7.9,"underlying":"Common Stock","underlying_shares":503478},"source":{"system":"sec-edgar","filing":"0001945691-25-000006","document":"form4-10282025_061001.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1945691/000194569125000006/form4-10282025_061001.xml","form_type":"4"}},{"id":1012660,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":24198,"kind":"person","name":"Kulkarni Sandeep Chidambar","position":1,"cik":"0001945691","reported_name":"Kulkarni Sandeep Chidambar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-10-28T22:30:05.000Z","date":"2025-10-28","kind":"other","planned":false,"acquired":false,"shares":7000,"ownership":{"direct":false,"nature":"By Gilead Capital, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland (\"Parent\"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the \"Shares\"), issued and outstanding immediately prior to the effective time of the merger (the \"Effective Time\"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, each Share was tendered in exchange for $48.00 in cash per Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held by Gilead Capital, LP (\"Gilead\"). The Reporting Person's spouse is a partner of Gilead and shares voting and investment power with respect to the shares held by Gilead, and therefore the Reporting Person may be deemed an indirect beneficial owner of these shares. This report is not an admission that the Reporting Person is an indirect beneficial owner of these shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001945691-25-000006","document":"form4-10282025_061001.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1945691/000194569125000006/form4-10282025_061001.xml","form_type":"4"}},{"id":1012659,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":24198,"kind":"person","name":"Kulkarni Sandeep Chidambar","position":1,"cik":"0001945691","reported_name":"Kulkarni Sandeep Chidambar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-10-28T22:30:05.000Z","date":"2025-10-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30387,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland (\"Parent\"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the \"Shares\"), issued and outstanding immediately prior to the effective time of the merger (the \"Effective Time\"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each restricted Share outstanding and subject to the Issuer's repurchase right as of immediately prior to the Effective Time became fully vested effective as of immediately prior to the Effective Time, and, by virtue of the merger and net of any applicable withholding taxes, was treated as a Share for all purposes under the terms of the Merger Agreement."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001945691-25-000006","document":"form4-10282025_061001.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1945691/000194569125000006/form4-10282025_061001.xml","form_type":"4"}},{"id":1012658,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":24198,"kind":"person","name":"Kulkarni Sandeep Chidambar","position":1,"cik":"0001945691","reported_name":"Kulkarni Sandeep Chidambar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-10-28T22:30:05.000Z","date":"2025-10-28","kind":"other","planned":false,"acquired":false,"shares":724664,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland (\"Parent\"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the \"Shares\"), issued and outstanding immediately prior to the effective time of the merger (the \"Effective Time\"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, each Share was tendered in exchange for $48.00 in cash per Share."}],"balance_after":30387,"source":{"system":"sec-edgar","filing":"0001945691-25-000006","document":"form4-10282025_061001.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1945691/000194569125000006/form4-10282025_061001.xml","form_type":"4"}},{"id":1013888,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":24198,"kind":"person","name":"Kulkarni Sandeep Chidambar","position":1,"cik":"0001945691","reported_name":"Kulkarni Sandeep Chidambar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-10-24T21:05:33.000Z","date":"2025-10-22","kind":"exercise","planned":false,"acquired":false,"shares":25316,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option vested as to 25% of the shares on June 14, 2024 with the remainder vesting in the following 36 equal monthly installments, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":503478,"derivative":{"exercise_price":7.9,"expiration_date":"2033-06-17","underlying":"Common Stock","underlying_shares":25316},"source":{"system":"sec-edgar","filing":"0001945691-25-000004","document":"form4-10242025_091030.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1945691/000194569125000004/form4-10242025_091030.xml","form_type":"4"}},{"id":1013887,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":24198,"kind":"person","name":"Kulkarni Sandeep Chidambar","position":1,"cik":"0001945691","reported_name":"Kulkarni Sandeep Chidambar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-10-24T21:05:33.000Z","date":"2025-10-22","kind":"exercise","planned":false,"acquired":true,"shares":25316,"price":7.9,"value":199996.4,"ownership":{"direct":true},"balance_after":755051,"source":{"system":"sec-edgar","filing":"0001945691-25-000004","document":"form4-10242025_091030.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1945691/000194569125000004/form4-10242025_091030.xml","form_type":"4"}},{"id":1137522,"issuer":{"id":5413,"kind":"organization","name":"Zura Bio Ltd"},"owners":[{"id":24198,"kind":"person","name":"Kulkarni Sandeep Chidambar","position":1,"cik":"0001945691","reported_name":"Kulkarni Sandeep Chidambar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2025-05-22T21:36:25.000Z","date":"2025-05-21","kind":"grant","planned":false,"acquired":true,"shares":51000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in twelve substantially equal monthly installments over a one-year period measured from May 21, 2025; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date."}],"balance_after":51000,"derivative":{"exercise_price":1.03,"expiration_date":"2035-05-21","underlying":"Class A Ordinary Shares","underlying_shares":51000},"source":{"system":"sec-edgar","filing":"0001415889-25-014221","document":"form4-05222025_090521.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1945691/000141588925014221/form4-05222025_090521.xml","form_type":"4"}},{"id":1285248,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":24198,"kind":"person","name":"Kulkarni Sandeep Chidambar","position":1,"cik":"0001945691","reported_name":"Kulkarni Sandeep Chidambar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-02-04T21:19:06.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":226000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest as to 25% of the shares on February 3, 2026, with the remainder vesting in 36 equal monthly installments, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":226000,"derivative":{"exercise_price":15.54,"expiration_date":"2035-02-02","underlying":"Common Stock","underlying_shares":226000},"source":{"system":"sec-edgar","filing":"0001827506-25-000014","document":"wk-form4_1738703938.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1945691/000182750625000014/wk-form4_1738703938.xml","form_type":"4"}},{"id":1335978,"issuer":{"id":5413,"kind":"organization","name":"Zura Bio Ltd"},"owners":[{"id":24198,"kind":"person","name":"Kulkarni Sandeep Chidambar","position":1,"cik":"0001945691","reported_name":"Kulkarni Sandeep Chidambar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2024-12-11T21:45:13.000Z","date":"2024-12-09","kind":"grant","planned":false,"acquired":true,"shares":117000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in twelve substantially equal monthly installments over a one-year period measured from October 23, 2024; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date."}],"balance_after":117000,"derivative":{"exercise_price":2.76,"expiration_date":"2034-12-09","underlying":"Class A Ordinary Shares","underlying_shares":117000},"source":{"system":"sec-edgar","filing":"0001415889-24-028975","document":"form4-12112024_041209.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1945691/000141588924028975/form4-12112024_041209.xml","form_type":"4"}},{"id":1425660,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":24198,"kind":"person","name":"Kulkarni Sandeep Chidambar","position":1,"cik":"0001945691","reported_name":"Kulkarni Sandeep Chidambar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2024-08-22T20:22:14.000Z","date":"2024-08-21","kind":"purchase","planned":false,"acquired":true,"shares":1779,"price":14.85,"value":26418.15,"ownership":{"direct":false,"nature":"By Gilead Capital, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.82 to $14.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Gilead Capital, LP (\"Gilead\"). The Reporting Person's spouse is a partner of Gilead and shares voting and investment power with respect to the shares held by Gilead, and therefore the Reporting Person may be deemed an indirect beneficial owner of these shares. This report is not an admission that the Reporting Person is an indirect beneficial owner of these shares for purposes of Section 16 or for any other purpose."}],"balance_after":7000,"source":{"system":"sec-edgar","filing":"0001827506-24-000076","document":"wk-form4_1724358128.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1945691/000182750624000076/wk-form4_1724358128.xml","form_type":"4"}},{"id":1427892,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":24198,"kind":"person","name":"Kulkarni Sandeep Chidambar","position":1,"cik":"0001945691","reported_name":"Kulkarni Sandeep Chidambar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2024-08-20T22:09:47.000Z","date":"2024-08-16","kind":"purchase","planned":false,"acquired":true,"shares":5221,"price":13.79,"value":71997.59,"ownership":{"direct":false,"nature":"By Gilead Capital, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.77 to $13.79 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Gilead Capital, LP (\"Gilead\"). The Reporting Person's spouse is a partner of Gilead and shares voting and investment power with respect to the shares held by Gilead, and therefore the Reporting Person may be deemed an indirect beneficial owner of these shares. This report is not an admission that the Reporting Person is an indirect beneficial owner of these shares for purposes of Section 16 or for any other purpose."}],"balance_after":5221,"source":{"system":"sec-edgar","filing":"0001827506-24-000074","document":"wk-form4_1724191780.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1945691/000182750624000074/wk-form4_1724191780.xml","form_type":"4"}},{"id":1734896,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":24198,"kind":"person","name":"Kulkarni Sandeep Chidambar","position":1,"cik":"0001945691","reported_name":"Kulkarni Sandeep Chidambar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2023-11-20T23:15:47.000Z","date":"2023-11-17","kind":"purchase","planned":false,"acquired":true,"shares":4000,"price":16.99,"value":67960.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.96 to $17.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":729735,"source":{"system":"sec-edgar","filing":"0001209191-23-056128","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1945691/000120919123056128/doc4.xml","form_type":"4"}},{"id":1754804,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":24198,"kind":"person","name":"Kulkarni Sandeep Chidambar","position":1,"cik":"0001945691","reported_name":"Kulkarni Sandeep Chidambar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2023-10-26T21:34:16.000Z","date":"2023-10-26","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":12.25,"value":61250.0,"ownership":{"direct":true},"balance_after":725735,"source":{"system":"sec-edgar","filing":"0001209191-23-053691","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1945691/000120919123053691/doc4.xml","form_type":"4"}},{"id":1754803,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":24198,"kind":"person","name":"Kulkarni Sandeep Chidambar","position":1,"cik":"0001945691","reported_name":"Kulkarni Sandeep Chidambar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2023-10-26T21:34:16.000Z","date":"2023-10-24","kind":"purchase","planned":false,"acquired":true,"shares":4650,"price":10.68,"value":49662.0,"ownership":{"direct":true},"balance_after":720735,"source":{"system":"sec-edgar","filing":"0001209191-23-053691","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1945691/000120919123053691/doc4.xml","form_type":"4"}},{"id":1756300,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":24198,"kind":"person","name":"Kulkarni Sandeep Chidambar","position":1,"cik":"0001945691","reported_name":"Kulkarni Sandeep Chidambar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2023-10-24T00:25:12.000Z","date":"2023-10-23","kind":"grant","planned":false,"acquired":true,"shares":254207,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares subject to the option vest as to 25% of the shares on October 23, 2024 with the remainder vesting in the following 36 equal monthly installments, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":254207,"derivative":{"exercise_price":9.46,"expiration_date":"2033-10-22","underlying":"Common Stock","underlying_shares":254207},"source":{"system":"sec-edgar","filing":"0001209191-23-053399","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1945691/000120919123053399/doc4.xml","form_type":"4"}},{"id":1756299,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":24198,"kind":"person","name":"Kulkarni Sandeep Chidambar","position":1,"cik":"0001945691","reported_name":"Kulkarni Sandeep Chidambar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2023-10-24T00:25:12.000Z","date":"2023-10-19","kind":"grant","planned":false,"acquired":true,"shares":528794,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Upon the closing of the Merger, each outstanding option to purchase shares of Tourmaline common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tourmaline stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split."},{"field":"shares","element":"transactionShares","label":"F3","text":"Upon the closing of the Merger, each outstanding option to purchase shares of Tourmaline common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tourmaline stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the closing of the Merger, each outstanding option to purchase shares of Tourmaline common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tourmaline stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Received in exchange for a stock option to acquire 6,629,000 shares of Tourmaline common stock pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option vest as to 25% of the shares on June 14, 2024 with the remainder vesting in the following 36 equal monthly installments, subject to the Reporting Person's continued service on each such vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"Upon the closing of the Merger, each outstanding option to purchase shares of Tourmaline common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tourmaline stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split."}],"balance_after":528794,"derivative":{"exercise_price":7.9,"expiration_date":"2033-06-17","underlying":"Common Stock","underlying_shares":528794},"source":{"system":"sec-edgar","filing":"0001209191-23-053399","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1945691/000120919123053399/doc4.xml","form_type":"4"}},{"id":1756298,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":24198,"kind":"person","name":"Kulkarni Sandeep Chidambar","position":1,"cik":"0001945691","reported_name":"Kulkarni Sandeep Chidambar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2023-10-24T00:25:12.000Z","date":"2023-10-19","kind":"grant","planned":false,"acquired":true,"shares":716085,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"134,591 of these shares are subject to a repurchase option in favor of the Issuer in the event that the Reporting Person's continuous service is terminated. Such repurchase option shall lapse in equal monthly installments until such shares are fully vested on June 1, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in exchange for 8,976,874 shares of common stock of Tourmaline Bio, Inc. (\"Tourmaline\") pursuant to an Agreement and Plan of Merger dated as of June 22, 2023 (the \"Merger Agreement\") by and among Tourmaline, the Issuer and Terrain Merger Sub, Inc., a wholly owned subsidiary of the Issuer (\"Merger Sub\"). Under the terms of the Merger Agreement, on October 19, 2023, Merger Sub merged with and into Tourmaline (the \"Merger\"), with Tourmaline surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Tourmaline common stock was converted into the right to receive 0.07977 of a share of the Issuer's common stock, after giving effect to a reverse stock split of the Issuer's common stock of 10-for-1. Subsequent to the Merger, the name of the Issuer was changed from Talaris Therapeutics, Inc. to Tourmaline Bio, Inc."}],"balance_after":716085,"source":{"system":"sec-edgar","filing":"0001209191-23-053399","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1945691/000120919123053399/doc4.xml","form_type":"4"}},{"id":1882902,"issuer":{"id":5413,"kind":"organization","name":"Zura Bio Ltd"},"owners":[{"id":24198,"kind":"person","name":"Kulkarni Sandeep Chidambar","position":1,"cik":"0001945691","reported_name":"Kulkarni Sandeep Chidambar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Share Option (Right to Buy)","published_at":"2023-05-23T01:17:39.000Z","date":"2023-05-18","kind":"grant","planned":false,"acquired":true,"shares":207520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the option shall become exercisable on May 18, 2024 and a further 2.083% of it shall become exercisable at the end of each month thereafter."}],"balance_after":207520,"derivative":{"exercise_price":5.31,"expiration_date":"2033-05-18","underlying":"Class A Ordinary Shares","underlying_shares":207520},"source":{"system":"sec-edgar","filing":"0001104659-23-063318","document":"tm2316481-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1945691/000110465923063318/tm2316481-7_4seq1.xml","form_type":"4"}}]}